177 Lu-DOTATATE Therapy: Effects of Water Intake and Drinking Duration on Patient Peripheral Dose Equivalent Rates.

Abstract

Abstract: This study investigated the amount and duration of water consumption in neuroendocrine tumor patients after receiving 177 Lu-DOTATATE radionuclide therapy. We recruited 39 patients with neuroendocrine tumors, all of whom were treated with 177 Lu-DOTATATE radionuclide while in the nuclear medicine ward of a tertiary hospital in Nanjing from January 2021 to April 2022. We conducted a cross-sectional survey to investigate their drinking times, water consumption, and urine volumes at 0 min, 30 min, 60 min, 2 h, 24 h, and 48 h after radionuclide treatment. At each timepoint, their radiation dose equivalent rates were monitored at 0 m, 1 m, and 2 m from the middle abdomen. f at 24 h were significantly lower than those at 0 min, 30 min, 60 min, and 2 h (all p < 0.05). The dose equivalent rates at 48 h were significantly lower than those at 24 h (all p < 0.05). At 1 m or 2 m from the patient, the dose equivalent rate gradually decreased at all six timepoints and was significantly different between groups ( P < 0.05). To achieve lower radiation doses, there was a correlation with 24 h water consumption (P < 0.05) but no correlation with 48 h water consumption (P > 0.05); there were lower peripheral dose equivalents for patients when 24 h water consumption was no less than 2,750 mL. Patients with neuroendocrine tumors should drink at least 2,750 mL of water 24 h after treatment with 177 Lu-DOTATATE radionuclides. Drinking water in the first 24 h after treatment is more critical to reduce the peripheral dose equivalent, which can accelerate the reduction of peripheral radiation dose equivalent in early patients.